LLY Hits Another Record High: Is the Stock Too Expensive to Buy Now?

Eli Lilly shares hit another record high as Wall Street confidence rises in its obesity and diabetes franchise. Despite the stock’s rich valuation, analysts remain focused on upside from the portfolio’s momentum rather than near-term negatives. Overall, the news is supportive but more sentiment-driven than a specific new catalyst.

Analysis

Eli Lilly shares hit another record high as Wall Street confidence rises in its obesity and diabetes franchise. Despite the stock’s rich valuation, analysts remain focused on upside from the portfolio’s momentum rather than near-term negatives. Overall, the news is supportive but more sentiment-driven than a specific new catalyst.